John Zhang
Chief Tech/Sci/R&D Officer chez IMMUNE PHARMACEUTICALS, INC.
Profil
John Zhang is currently the Vice President of Research & Development at Immune Pharmaceuticals, Inc. He previously worked as the Director of Preclinical Pharmacology & Toxicology at Pharmacopeia LLC, Head of Toxicology at Enzon Pharmaceuticals, Inc., and Vice President of Preclinical Research & Development at EnzymeRx LLC.
He holds a graduate degree from the University of California, Los Angeles and a doctorate degree from Guangzhou University.
Postes actifs de John Zhang
| Sociétés | Poste | Début |
|---|---|---|
| IMMUNE PHARMACEUTICALS, INC. | Chief Tech/Sci/R&D Officer | 11/12/2017 |
Anciens postes connus de John Zhang
| Sociétés | Poste | Fin |
|---|---|---|
Pharmacopeia LLC
 Pharmacopeia LLC Pharmaceuticals: MajorHealth Technology Pharmacopeia LLC develops small molecule therapeutics to address significant medical needs. The firm operates as clinical development stage Biopharmaceutical Company which focuses on discovering and developing novel small molecule therapeutics to address medical needs. The company was founded by John J. Baldwin in February 2002 and is headquartered in Cranbury, NJ. | Corporate Officer/Principal | - |
| ENZON PHARMACEUTICALS, INC. | Corporate Officer/Principal | - |
EnzymeRx LLC
 EnzymeRx LLC BiotechnologyHealth Technology EnzymeRx LLC develops pegylated uricase for the treatment of resistant and refractory related indications. The company was founded by Anthony S Fiorino in 2008 and is headquartered in Paramus, NJ. | Chief Tech/Sci/R&D Officer | - |
Formation de John Zhang
| University of California, Los Angeles | Graduate Degree |
| Guangzhou University | Doctorate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| ENZON PHARMACEUTICALS, INC. | Health Technology |
| Entreprise privées | 3 |
|---|---|
Pharmacopeia LLC
Pharmacopeia LLC Pharmaceuticals: MajorHealth Technology Pharmacopeia LLC develops small molecule therapeutics to address significant medical needs. The firm operates as clinical development stage Biopharmaceutical Company which focuses on discovering and developing novel small molecule therapeutics to address medical needs. The company was founded by John J. Baldwin in February 2002 and is headquartered in Cranbury, NJ. | Health Technology |
EnzymeRx LLC
EnzymeRx LLC BiotechnologyHealth Technology EnzymeRx LLC develops pegylated uricase for the treatment of resistant and refractory related indications. The company was founded by Anthony S Fiorino in 2008 and is headquartered in Paramus, NJ. | Health Technology |
Immune Pharmaceuticals, Inc.
 Immune Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Immune Pharmaceuticals, Inc. is a biopharmaceutical company developing novel therapeutic agents for the treatment of immunologic and inflammatory diseases. Its lead product, Bertilimumab, is a human monoclonal antibody that binds eotaxin-1, a chemokine that attracts eosinophils to the site of inflammation. Bertilimumab has shown promising clinical activity in bullous pemphigoid and has been studied in other conditions including allergic rhinitis and ulcerative colitis, and may have application in other diseases, including atopic dermatitis, asthma, and other diseases. It is also developing NanoCyclo, a topical nano-encapsulated formulation of cyclosporine, for the treatment of atopic dermatitis (AD) and psoriasis. The company was founded by Daniel Gedeon Teper on March 9, 1993 and is headquartered in Englewood Cliffs, NJ. | Health Technology |
